An oral antiviral for Ebola disease
成果类型：
Editorial Material
署名作者：
Sprecher, Armand; Van Herp, Michel
署名单位：
Doctors Without Borders
刊物名称：
SCIENCE
ISSN/ISSBN：
0036-12473
DOI：
10.1126/science.ado6257
发表日期：
2024-03-15
页码：
1181-1182
关键词：
摘要：
Marburg disease and Ebola disease-which includes Ebola virus disease (EVD) and Sudan virus disease (SVD)-are collectively called filovirus diseases (FVDs). These cause considerable mortality. During outbreaks, when a case of FVD is identified, their close contacts receive a daily visit from follow-up teams for 21 days, which is the extent of the incubation period. If a contact becomes ill, they are brought to a treatment unit, where they remain if they have FVD. This procedure should minimize spreading of FVD, but a substantial flaw is that people who have been exposed to someone with FVD are scared about the gravity of the disease and the limits of what can be done for them, and so they do not always volunteer for surveillance and isolation. On page 1195 of this issue, Cross et al. ( 1 ) report the efficacy of the oral antiviral drug obeldesivir in protecting cynomolgus macaques after SVD challenge, which could change attitudes toward surveillance.